Pfizer Inc. $PFE Shares Bought by Donoghue Forlines LLC

Donoghue Forlines LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 6.3% in the 2nd quarter, Holdings Channel.com reports. The fund owned 60,168 shares of the biopharmaceutical company’s stock after buying an additional 3,576 shares during the period. Donoghue Forlines LLC’s holdings in Pfizer were worth $1,458,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Capital Advisory Group Advisory Services LLC increased its stake in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares in the last quarter. Citizens National Bank Trust Department grew its holdings in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 395 shares during the last quarter. Able Wealth Management LLC increased its position in shares of Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 413 shares during the period. Trust Co of the South raised its stake in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares during the last quarter. Finally, Charter Oak Capital Management LLC lifted its position in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 444 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on PFE shares. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Scotiabank began coverage on shares of Pfizer in a research note on Thursday. They set a “sector outperform” rating and a $30.00 price objective for the company. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.80 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company’s fifty day moving average price is $24.79 and its 200 day moving average price is $24.43. The company has a market capitalization of $146.66 billion, a PE ratio of 13.72, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.